Creo Medical Ltd, a Chepstow, UK-based developer of innovative medical devices, closed a £3.5m funding round.
The company, which has raised £7.9m to date, intends to use the funds for the continuing development of its (CROMA) platform to achieve regulatory approval for the European market, and establish a regulatory pathway into the US market.
Founded in 2009 and led by Craig Gulliford, CEO, Creo Medical has developed a Microwave and Bipolar Radiofrequency energy platform that enables precise tissue effects to be created with a range of clinically relevant instruments.
Its first instrument performs flexible endoscopic dissection of tissue abnormalities within the Gastrointestinal Tract. The CROMA platform and product range will then be expanded into other areas of treatment such as laparoscopic or general surgery.